PT2786753T - Terapia de combinação com um antibiótico antitumoral - Google Patents

Terapia de combinação com um antibiótico antitumoral

Info

Publication number
PT2786753T
PT2786753T PT14175259T PT14175259T PT2786753T PT 2786753 T PT2786753 T PT 2786753T PT 14175259 T PT14175259 T PT 14175259T PT 14175259 T PT14175259 T PT 14175259T PT 2786753 T PT2786753 T PT 2786753T
Authority
PT
Portugal
Prior art keywords
combination therapy
antitumor alkaloid
alkaloid
antitumor
therapy
Prior art date
Application number
PT14175259T
Other languages
English (en)
Inventor
María Galmarini Carlos
Moneo Ocaña Victoria
Francisco García Fernández Luis
José Guillén Navarro María
Manuel Avilés Marín Pablo
Santamaría Núñez Gema
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of PT2786753T publication Critical patent/PT2786753T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
PT14175259T 2010-11-12 2011-11-11 Terapia de combinação com um antibiótico antitumoral PT2786753T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10382300 2010-11-12

Publications (1)

Publication Number Publication Date
PT2786753T true PT2786753T (pt) 2019-04-24

Family

ID=44936282

Family Applications (3)

Application Number Title Priority Date Filing Date
PT14175259T PT2786753T (pt) 2010-11-12 2011-11-11 Terapia de combinação com um antibiótico antitumoral
PT14175268T PT2786754T (pt) 2010-11-12 2011-11-11 Terapia de combinação com um inibidor mitótico
PT141752824T PT2786756T (pt) 2010-11-12 2011-11-11 Terapia de combinação com um inibidor de topoisomerase

Family Applications After (2)

Application Number Title Priority Date Filing Date
PT14175268T PT2786754T (pt) 2010-11-12 2011-11-11 Terapia de combinação com um inibidor mitótico
PT141752824T PT2786756T (pt) 2010-11-12 2011-11-11 Terapia de combinação com um inibidor de topoisomerase

Country Status (24)

Country Link
US (5) US20130266666A1 (pt)
EP (6) EP2786755A3 (pt)
JP (4) JP6382516B2 (pt)
KR (9) KR20170096224A (pt)
CN (3) CN106860870B (pt)
AU (4) AU2011328004C1 (pt)
BR (4) BR122017028568B1 (pt)
CA (4) CA2995025C (pt)
CY (4) CY1117466T1 (pt)
DK (4) DK2786753T3 (pt)
ES (4) ES2790414T3 (pt)
HK (5) HK1202423A1 (pt)
HR (4) HRP20160361T1 (pt)
HU (4) HUE042801T2 (pt)
LT (3) LT2786754T (pt)
ME (3) ME03408B (pt)
PL (4) PL2786756T3 (pt)
PT (3) PT2786753T (pt)
RS (4) RS58609B1 (pt)
RU (4) RU2743643C2 (pt)
SI (4) SI2786753T1 (pt)
SM (1) SMT201600112B (pt)
TR (2) TR201903859T4 (pt)
WO (1) WO2012062920A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8491927B2 (en) * 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
RU2743643C2 (ru) * 2010-11-12 2021-02-20 Фарма Мар, С.А. Комбинированная терапия противоопухолевым алкалоидом
US11491154B2 (en) 2013-04-08 2022-11-08 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
KR101588949B1 (ko) * 2014-03-13 2016-01-29 아주대학교산학협력단 플루나리진을 유효성분으로 함유하는 뇌암에 대한 항암 활성 보조제
US11326210B2 (en) * 2015-01-30 2022-05-10 Glax Llc Compositions and methods for monitoring, diagnosis, prognosis, detection, and treatment of cancer
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
KR20210049403A (ko) * 2019-10-25 2021-05-06 연세대학교 산학협력단 암의 예방 또는 치료용 조성물
AU2020388196A1 (en) * 2019-11-21 2022-06-30 Pharma Mar, S.A. Methods of treating small cell lung cancer with lurbinectedin formulations
MA56827B2 (fr) * 2019-11-21 2023-09-27 Pharma Mar Sa Procédés de traitement du cancer du poumon à petites cellules avec des formulations de lurbinectédine
WO2021228414A1 (en) * 2020-05-14 2021-11-18 Pharma Mar, S.A. Methods of treating small cell lung cancer with lurbinectedin formulations
CN111298122B (zh) * 2019-12-04 2021-12-21 哈尔滨商业大学 用于治疗小细胞肺癌的药物组合物及其应用
CN113491771A (zh) * 2020-03-18 2021-10-12 苏州大学 小分子化合物在制备glut5摄取转运果糖的抑制剂中的应用
EP4141110A1 (en) 2020-04-24 2023-03-01 Obshchestvo S Ogranichennoy Otvetstvennost'yu "Ingenik" Method for producing particles of bacteriophages of the genus levivirus
CN114470216A (zh) * 2020-10-23 2022-05-13 和记黄埔医药（上海）有限公司 多受体酪氨酸激酶抑制剂与化疗剂的药物组合及其使用方法
CN112870194B (zh) * 2021-01-06 2022-06-21 广州医科大学附属肿瘤医院 治疗肝癌的组合物及其应用
CN115246846A (zh) * 2021-11-19 2022-10-28 江苏慧聚药业股份有限公司 卢比替定新晶型及其制备
WO2023165603A1 (en) * 2022-03-03 2023-09-07 Zai Lab (Shanghai) Co., Ltd. Dna-pk inhibitor and combination use thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59225189A (ja) 1983-06-03 1984-12-18 Shionogi & Co Ltd キノナミン誘導体およびその製造法
JPS6084288A (ja) 1983-10-13 1985-05-13 Shionogi & Co Ltd シアノキノナミンアセテ−ト類およびその製造法
US5089273A (en) 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5256663A (en) 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5149804A (en) 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
WO1987007610A2 (en) 1986-06-09 1987-12-17 University Of Illinois Ecteinascidins 729, 743, 745, 759a, 759b and 770
US5478932A (en) 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US5721362A (en) 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
US5985876A (en) 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
BR9909488B1 (pt) 1998-04-06 2011-02-08 ecteinascidinas semi-sintéticas e composição farmacêutica.
EP1077698B1 (en) 1998-05-11 2005-03-02 Pharma Mar, S.A. Metabolites of ecteinascidin 743
US6124292A (en) 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
US7311924B2 (en) * 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
MY130271A (en) * 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
AU783562B2 (en) 2000-01-19 2005-11-10 Trustees Of Columbia University In The City Of New York, The Compounds of the saframycin-ecteinascidin series, uses, and synthesis thereof
CA2406080C (en) 2000-04-12 2011-11-29 Pharma Mar, S.A. Antitumoral ecteinascidin derivatives
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
CA2428160C (en) * 2000-11-06 2009-10-13 Pharma Mar, S.A. Compositions for antitumor treatment containing ecteinascidin 743
SE0102232L (sv) 2001-06-25 2003-02-06 Anoto Ab Förfarande och anordning i ett digitalt kommunikationssystem
GB0119243D0 (en) * 2001-08-07 2001-10-03 Pharma Mar Sa Antitumoral analogs of ET-743
ES2362998T3 (es) * 2002-08-19 2011-07-18 Pfizer Inc. Terapia de combinación para enfermedades hiperproliferativas.
ES2357644T3 (es) 2002-10-18 2011-04-28 Pharma Mar, S.A.U. Compuesto 4-metilhexanoico kahalalido f.
FR2856688B1 (fr) 2003-06-25 2008-05-30 Sod Conseils Rech Applic PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX
US7393277B2 (en) * 2003-08-25 2008-07-01 Igt Horseshoe payline system and games using that system
RS50692B (sr) * 2003-11-13 2010-06-30 Pharma Mar S.A.U. Kombinacija et-743 sa prolekovima 5-fluorouracila za lečenje kancera
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
AU2004291037A1 (en) * 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of ET-743 and paclitaxel for treating cancer
JP2008501007A (ja) * 2004-05-28 2008-01-17 ファイザー・プロダクツ・インク 異常な細胞増殖を治療するための方法
DE602005001833T2 (de) 2004-10-29 2008-04-17 Pharma Mar S.A., Sociedad Unipersonal Zusammensetzungen enthaltend Ecteinascidin und einen Disaccharide
DK1827437T3 (da) 2004-12-15 2012-02-13 Sigma Tau Ind Farmaceuti Kombinationer af terapeutiske midler til cancerbehandling
TW200744603A (en) * 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
PL2029155T3 (pl) * 2006-02-28 2016-09-30 Ulepszony sposób leczenia szpiczaka mnogiego
RU2010151602A (ru) * 2008-05-16 2012-06-27 Фарма Мар, С.А. (Es) Комбинированная терапия с помощью рм00104 и другого противоопухолевого средства
RU2743643C2 (ru) * 2010-11-12 2021-02-20 Фарма Мар, С.А. Комбинированная терапия противоопухолевым алкалоидом

Also Published As

Publication number Publication date
EP2786756B1 (en) 2020-03-11
US20180078551A1 (en) 2018-03-22
BR122017028566B1 (pt) 2022-03-03
DK2786753T3 (en) 2019-04-15
EP3666275A3 (en) 2020-09-09
PL2637663T3 (pl) 2016-08-31
JP6723815B2 (ja) 2020-07-15
CA2995025A1 (en) 2012-05-18
US20230404999A1 (en) 2023-12-21
DK2637663T3 (en) 2016-04-18
CN103282037B (zh) 2017-04-05
EP2786754A3 (en) 2014-10-29
RU2016144668A (ru) 2018-12-18
KR20170058454A (ko) 2017-05-26
LT2786753T (lt) 2019-04-10
US20180078550A1 (en) 2018-03-22
ES2790414T3 (es) 2020-10-27
EP2786753A2 (en) 2014-10-08
BR112013011480B1 (pt) 2022-03-22
AU2017276157B2 (en) 2019-03-07
ES2719091T3 (es) 2019-07-08
AU2011328004B2 (en) 2016-07-14
RS58609B1 (sr) 2019-05-31
CA2817420C (en) 2019-09-24
EP2786755A3 (en) 2014-10-29
HUE027516T2 (en) 2016-10-28
BR112013011480A2 (pt) 2016-08-09
LT2786756T (lt) 2020-05-11
HK1202419A1 (en) 2015-10-02
HK1202422A1 (en) 2015-10-02
AU2016200191A1 (en) 2016-02-04
HK1202421A1 (en) 2015-10-02
HRP20200696T1 (hr) 2020-07-24
RU2018102080A3 (pt) 2021-04-12
EP2637663B1 (en) 2016-02-24
KR101716804B1 (ko) 2017-03-15
EP2786753A3 (en) 2014-10-29
HRP20160361T1 (hr) 2016-05-06
SI2786753T1 (sl) 2019-05-31
CN103282037A (zh) 2013-09-04
RS54648B1 (en) 2016-08-31
AU2011328004A1 (en) 2013-05-30
CA2995033A1 (en) 2012-05-18
RS60236B1 (sr) 2020-06-30
ME03408B (me) 2020-01-20
ME03501B (me) 2020-04-20
SI2637663T1 (sl) 2016-05-31
EP2786754A2 (en) 2014-10-08
CY1121501T1 (el) 2020-05-29
EP2786754B1 (en) 2019-01-09
ES2569180T3 (es) 2016-05-09
JP6724056B2 (ja) 2020-07-15
CY1117466T1 (el) 2017-04-26
RS58608B1 (sr) 2019-05-31
ME02395B (me) 2016-09-20
CN106860870B (zh) 2020-03-31
KR20170096065A (ko) 2017-08-23
PL2786754T3 (pl) 2019-07-31
PL2786753T3 (pl) 2019-09-30
RU2767664C2 (ru) 2022-03-18
BR122017028570B1 (pt) 2022-03-03
HK1188572A1 (zh) 2014-05-09
KR20160088956A (ko) 2016-07-26
AU2011328004C1 (en) 2017-01-19
KR20170057472A (ko) 2017-05-24
RU2013126630A (ru) 2014-12-20
HRP20190565T1 (hr) 2019-05-17
JP2018100302A (ja) 2018-06-28
KR102247982B1 (ko) 2021-05-04
TR201904459T4 (tr) 2019-05-21
US20130266666A1 (en) 2013-10-10
KR20190130078A (ko) 2019-11-20
HK1202423A1 (en) 2015-10-02
RU2018102078A3 (pt) 2021-04-20
LT2786754T (lt) 2019-04-10
HRP20190554T1 (hr) 2019-05-03
BR122017028568B1 (pt) 2022-03-03
JP2013542241A (ja) 2013-11-21
CN106860870A (zh) 2017-06-20
JP2018100303A (ja) 2018-06-28
RU2757373C2 (ru) 2021-10-14
SI2786756T1 (sl) 2020-07-31
RU2016144668A3 (pt) 2020-03-25
AU2016200191B2 (en) 2018-01-18
SI2786754T1 (sl) 2019-05-31
CN105664165A (zh) 2016-06-15
HUE042801T2 (hu) 2019-07-29
JP6382516B2 (ja) 2018-08-29
JP2016138133A (ja) 2016-08-04
CA2995018A1 (en) 2012-05-18
KR20170124641A (ko) 2017-11-10
KR102452022B1 (ko) 2022-10-06
EP2637663A1 (en) 2013-09-18
AU2017276155B2 (en) 2019-03-07
JP6724055B2 (ja) 2020-07-15
HUE049389T2 (hu) 2020-09-28
RU2743643C2 (ru) 2021-02-20
BR112013011480A8 (pt) 2018-01-02
ES2719052T3 (es) 2019-07-08
US11590129B2 (en) 2023-02-28
KR102301175B1 (ko) 2021-09-10
CY1122904T1 (el) 2021-10-29
WO2012062920A1 (en) 2012-05-18
DK2786754T3 (en) 2019-04-15
EP2786756A3 (en) 2014-10-29
KR20170096224A (ko) 2017-08-23
CA2995033C (en) 2020-04-28
EP2786753B1 (en) 2019-01-09
RU2018102078A (ru) 2019-07-19
PT2786756T (pt) 2020-05-07
TR201903859T4 (tr) 2019-04-22
AU2017276157A1 (en) 2018-01-04
SMT201600112B (it) 2016-07-01
HUE042802T2 (hu) 2019-07-29
KR20130140071A (ko) 2013-12-23
EP2786756A2 (en) 2014-10-08
CA2817420A1 (en) 2012-05-18
US20180008602A1 (en) 2018-01-11
CA2995025C (en) 2020-04-28
AU2017276155A1 (en) 2018-01-04
RU2018102080A (ru) 2019-07-19
KR20210046853A (ko) 2021-04-28
CY1121504T1 (el) 2020-05-29
EP3666275A2 (en) 2020-06-17
DK2786756T3 (en) 2020-04-27
RU2605335C2 (ru) 2016-12-20
PT2786754T (pt) 2019-04-24
CA2995018C (en) 2021-04-20
PL2786756T3 (pl) 2020-07-13
EP2786755A2 (en) 2014-10-08

Similar Documents

Publication Publication Date Title
HRP20190554T1 (hr) Kombinacijska terapija s protutumorskim antibiotikom
HUS1800042I1 (hu) Antivirális terápia
IL222481A0 (en) Combination therapy
EP2552323A4 (en) COMBINATION THERAPY
ZA201401952B (en) Immunocytokine combination therapy
ZA201300967B (en) Combination anti-cancer therapy
GB201005394D0 (en) Therapy
EP2629766A4 (en) COMBINATION THERAPY